---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026392"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-03-21T23:59:59+00:00"
generated_at: "2026-05-24T08:25:25.832644+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma tivoxavir marboxil shows 100% survival in H5N1 rodent model; Phase 1 PK positive

## Summary
- 100% of TXM-treated mice survived lethal H5N1 challenge; all untreated controls died by study day 6.
- Single 240 mg dose maintained plasma levels at EC90 for ~25 days; well tolerated up to 480 mg in Phase 1.
- TXM exhibited sub-nanomolar EC50 against circulating 2022-2023 H5N1 strains and baloxavir-resistant viruses.
- Investor call scheduled for March 31, 2025 at 10:00 AM ET to review antiviral programs.

## SEC filing metadata
- accession: 0001104659-25-026392
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-03-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925026392/0001104659-25-026392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925026392/tm259925d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026392
- JSON: https://secwatch.observer/filing/0001104659-25-026392.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.